Skip to main content

Advertisement

SpringerLink
Log in

High Times, Low Sats: Diffuse Pulmonary Infiltrates Associated with Chronic Synthetic Cannabinoid Use

  • Toxicology Observation
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Introduction

In recent years, cases of severe adverse effects from recreational use of synthetic cannabinoids (SC) have established that these agents represent a novel toxicologic hazard.

Case Report

A 21-year-old male presenting as a vehicular trauma victim was noted with diffuse pulmonary infiltrates related to chronic inhalation of multiple synthetic cannabinoid-containing products. Chest imaging revealed bilateral, subacute lung infiltrates; histopathological analysis of bronchial and alveolar tissues revealed an inflammatory process. An extensive workup failed to identify infectious, malignant, autoimmune, or hematologic causes of the syndrome, and toxicological analysis of the blood and body fluids confirmed the presence of multiple synthetic cannabinoids and metabolites. The patient recovered after an 8-day ICU course, wherein he received antibiotics, steroids, and mechanical ventilation.

Discussion

This case contributes to the currently evolving knowledge about SC agents, adding a rarely described pulmonary complication to the growing list of adverse effects associated with these products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Wells DL, Ott CA (2011) The “new” marijuana. Ann Pharmacother 45(3):414–417

    Article  PubMed  CAS  Google Scholar 

  2. Vearrier D, Osterhoudt K (2010) A teenager with agitation: higher than she should have climbed. Ped Emerg Care 26(6):462-465

    Google Scholar 

  3. Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012 Apr 26

  4. Logan BK, Reinhold LE, Xu A, Diamond FX (2012) Identification of synthetic cannabinoids in herbal incense blends in the United States. J Forensic Sci 2012 Jul 26

  5. Tofighi B, Lee JD (2012) Internet highs-seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 6(3):240–241

    Article  PubMed  Google Scholar 

  6. Forrester M, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 2012 Aug 2

  7. Cohen J, Morrison S, Greenberg J, Saidinejad M (2012) Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129(4):e1064–e1067

    Article  PubMed  Google Scholar 

  8. Ashton JC (2012) Synthetic cannabinoids as drugs of abuse. Curr Drug Abuse Rev 5(2):158–168

    Article  PubMed  CAS  Google Scholar 

  9. Castellanos D, Thornton G (2012) Synthetic cannabinoid use: recognition and management. J Psychiatr Pract 18(2):86–93

    Article  PubMed  Google Scholar 

  10. Rosenbaum CD, Carreiro SP, Babu KM (2012) Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8(1):15–32

    Article  PubMed  CAS  Google Scholar 

  11. Vardakou I, Pistos C, Spiliopoulou C (2010) Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197(3):157–162

    Article  PubMed  CAS  Google Scholar 

  12. Atwood BK, Huffman JW, Straiker A et al (2010) JWH018, a common consitiuent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br J Pharm 160:585–593

    Article  CAS  Google Scholar 

  13. Simmons JR, Skinner CG, Williams J et al (2011) Intoxication from smoking “Spice. Ann Emerg Med 57(2):187–188

    Article  PubMed  Google Scholar 

  14. Schneir AB, Cullen J, Ly BT (2011) “Spice” girls: synthetic cannabinoid intoxication. J Emerg Med 40(3):296–299

    Article  PubMed  Google Scholar 

  15. Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128(6):e1622–e1627

    Article  PubMed  Google Scholar 

  16. Hurst D, Loeffler G, McLay R (2011) Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 168(10):1119

    Article  PubMed  Google Scholar 

  17. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, Kleinschmidt K (2011) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2011 Jul 28

  18. Fattore L, Fratta W (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5(60):1–12

    Google Scholar 

  19. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA (2007) Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 167:221–228

    Article  PubMed  Google Scholar 

  20. Lieberman CM, Lieberman BW (1971) Marihuana—a medical review. N Engl J Med 284:88–91

    Article  PubMed  CAS  Google Scholar 

  21. Guidotti TL, Laing L, Prakash UB (1989) Clove cigarettes. The basis for concern regarding health effects. West J Med 151(2):220–228

    PubMed  CAS  Google Scholar 

  22. Bennett GL, Chew FS (1994) Pulmonary carcinoid tumorlets. AJR 162:568

    Article  PubMed  CAS  Google Scholar 

  23. Loschner A, Cihla A, Jalali F et al (2011) Diffuse alveolar hemorrhage: add “greenhouse effect” to the growing list. Chest 140:149A

    Article  Google Scholar 

  24. Selman M, Pardo A, King TE (2012) Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 186(4):314–324

    Article  PubMed  CAS  Google Scholar 

  25. Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal. doi:10.1002/dta.1418

  26. McQuade D, Hudson S, Dargan PI, Wood D (2012) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol. doi:10.1007/s00228-012-1379-2

  27. EkaJ (20 February 2011). “The night i killed my friends”. Erowid.org. Retrieved 2 Dec 2012. http://www.Erowid.org/experiences/exp.php?ID=89294

Download references

Author information

Authors and Affiliations

  1. UCSF-Fresno Medical Center, Fresno, CA, USA

    Sameir Alhadi, Anupama Tiwari, Rais Vohra, Janak Acharya & Kathryn Bilello

  2. UCSF School of Medicine, San Francisco General Hospital, San Francisco, CA, USA

    Roy Gerona

Authors
  1. Sameir Alhadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anupama Tiwari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rais Vohra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roy Gerona
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janak Acharya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kathryn Bilello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rais Vohra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alhadi, S., Tiwari, A., Vohra, R. et al. High Times, Low Sats: Diffuse Pulmonary Infiltrates Associated with Chronic Synthetic Cannabinoid Use. J. Med. Toxicol. 9, 199–206 (2013). https://doi.org/10.1007/s13181-013-0288-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-013-0288-9

Keywords

Search

Navigation